Clinical and molecular data live in separate worlds

How multimodal platforms connect the two worlds

The platforms in this space typically sit close to the data's origin — operating sequencing laboratories, partnering with health systems, or aggregating from both — so molecular results and clinical histories arrive already attached to the same de-identified patient. Structuring does the rest of the work: variant calls, biomarker statuses, and report findings are normalized into queryable fields, and clinical context (diagnoses, treatments, outcomes) is curated alongside them, often with AI-assisted extraction from unstructured records. The scale caveat is real: multimodal depth exists mainly where testing is routine — oncology far ahead of other therapeutic areas — and cohort sizes shrink fast as molecular criteria narrow. The evaluation question is whether the linked cohort matching your specific profile is large and deep enough for the analysis you intend, not the platform's total volume.

What to evaluate before licensing multimodal data

Define the exact cohort your science needs — molecular criteria, treatment exposure, outcome measures, follow-up duration — and ask the vendor to size it before any commitment. Probe how outcomes are derived, because outcome quality is where multimodal datasets differ most: dates and codes come cheap, while response and progression typically require curation from notes and imaging reports, and the method behind them determines whether survival-style analyses are credible. Ask equally hard questions about consent and provenance: under what terms the molecular data was collected, whether the consent covers your intended research use, and how the vendor handles the elevated re-identification sensitivity that genomic data carries.

How teams typically get started

Translational teams usually start with a question they cannot currently answer — how a biomarker-defined subgroup responds to standard of care, or how a resistance profile evolves across lines of therapy — and commission a feasibility count before licensing anything. Running one such analysis end to end reveals what matters: whether the cohort held up under real inclusion criteria, whether the curated outcomes survived scrutiny, and whether the data integrated into the team's analysis environment or stayed trapped in the vendor's portal.

AI Use Cases That Address This Problem

• Patient Recruitment & Enrollment
• Target Identification & Validation

Frequently asked questions

Why is oncology so far ahead in multimodal data?

Because molecular testing is routine clinical practice there — most patients generate sequencing data as part of care, so linked clinical-molecular records accumulate at scale. In therapeutic areas where testing is rarer, linked cohorts are smaller and multimodal platforms have proportionally less to offer; feasibility counts matter even more.

What makes curated outcomes trustworthy?

A documented method: which source documents were used, how response or progression was defined, whether abstraction was human, machine-assisted, or both, and what accuracy was measured against expert review. Outcomes without a described derivation method should be treated as unverified.

Does genomic data raise special privacy concerns?

Yes — a genome is inherently identifying in a way most data is not, so de-identification standards, access controls, and consent scope deserve sharper scrutiny than for claims or EHR data alone. Ask vendors specifically how consent was obtained for research use and how they mitigate re-identification risk in small molecular subgroups.

Platform data or our own biobank — which serves discovery better?

They answer different needs: internal biobanks offer depth and control over exactly the samples you chose to collect; platforms offer breadth, real-world treatment diversity, and immediate availability. Discovery programs commonly use platform data to generate and size hypotheses, then validate on internal or prospective cohorts.

AI Vendors for This Problem

• BenevolentAI
• Cellarity
• ConcertAI
• Deep Genomics
• Envisagenics
• Healx
• Immunai
• Inato
• Insilico Medicine
• Isomorphic Labs
• Lindus Health
• Medidata Solutions
• NVIDIA BioNeMo
• OneStudyTeam
• Owkin
• Recursion Pharmaceuticals
• Standigm
• Tempus AI
• TriNetX
• Trial Library
• Trially AI
• Triomics
• Turbine
• Valo Health
• Verana Health

Evidence & Outcomes